Calaspargase Pegol

Class

• Antineoplastic agent – Enzyme (Asparaginase family, PEGylated).
• Long-acting PEGylated form of L-asparaginase.

Mechanism of Action

• Leukemic lymphoblasts lack or have very low activity of asparagine synthetase, making them dependent on extracellular asparagine.
• Calaspargase pegol catalyzes the hydrolysis of asparagine → aspartic acid + ammonia.
• Result:
  • Depletion of circulating asparagine → inhibition of protein synthesis → apoptosis of leukemic cells.
  • Normal cells can synthesize asparagine, so less affected.

Indication

• Acute Lymphoblastic Leukemia (ALL) in pediatric (≥1 month) and young adult patients (up to 21 years) as part of a multi-agent chemotherapy regimen.

Pharmacology

• Pegylated form of E. coli–derived asparaginase.
• Longer half-life than pegaspargase (t½ ~16 days vs ~5–6 days).
• Allows every-3-week dosing, improving compliance compared with pegaspargase (q2 weeks).

Dosing (FDA-approved)

• 2,500 units/m² IV over 1 hour, every 21 days.
• No intramuscular route (IV only).
• Usually capped at maximum dose: 3,750 units.

Toxicities & Monitoring

Similar to other asparaginases:

1. Hypersensitivity / Anaphylaxis
   • Less common with PEGylation, but still possible.
   • Monitor during infusion; premedication not routine unless prior mild reaction.
2. Pancreatitis (can be life-threatening)
   • Monitor for abdominal pain, elevated amylase/lipase.
   • Discontinue permanently if grade ≥3 pancreatitis or hemorrhagic/necrotizing.
3. Hepatotoxicity
   • Elevated bilirubin, transaminases, hypoalbuminemia, hepatic failure.
   • Monitor LFTs and coagulation parameters.
4. Thrombosis and Bleeding
   • Alters protein C, S, antithrombin III → ↑ risk of VTE/bleeding.
   • Monitor coagulation studies; use anticoagulation only if clinically indicated.
5. Hyperglycemia (due to reduced insulin synthesis).
   • Monitor glucose, especially if also receiving steroids.
6. CNS toxicity (secondary to thrombosis or metabolic disturbances).

Clinical Advantages over Pegaspargase

• Extended dosing interval (q3 weeks vs q2 weeks).
• More predictable pharmacokinetics → sustained asparagine depletion.
• May reduce hospital visits and improve adherence.

Monitoring Parameters

• CBC, LFTs, amylase/lipase, fasting glucose.
• Coagulation profile (PT, aPTT, fibrinogen, antithrombin III).
• Observe for infusion reactions during and after infusion.

Key Clinical Pearl for Oncology Pharmacist:

Calaspargase is essentially a longer-acting, IV-only PEG-asparaginase. Its major value is reducing dosing frequency (q3 weeks) while maintaining effective asparagine depletion in ALL protocols, but vigilance for pancreatitis, thrombosis, and hepatotoxicity remains critical.